SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
SwanBio have released a press release about their AMN natural history study using wearable technology – with the data collected to provide insights for future first-in-human study of SBT101, AAV-based gene therapy for AMN.
Aspa Therapeutics has announced new data from the CANaspire gene therapy clinical trial
Aspa Therapeutics, a BridgeBio company, has announced new data from the CANaspire gene therapy clinical trial.
The government is looking to reform disabled children’s services through a set of proposed policies in the ‘SEND Green Paper’. The government’s plans contain several worrying proposals that could further weaken the rights of families with disabled children and make it even harder for them to access support.
Are you a family member, carer or guardian of a child (under the age of 16 who is currently risk feeding or has risk fed in the past? Do you have experience with risk-feeding discussions and decisions with medical professionals?
Risk feeding (also sometimes known as comfort feeding or eating and drinking with acknowledged risk), is when a child eats and drinks with the knowledge that they risk choking or aspirating when doing so. Currently decisions in this area do not follow a protocol, which affects standardisation of practice. To resolve this issue, we are looking for family members, carers or guardians with experience of being involved in paediatric risk-feeding decisions and discussions with children under the age of 16 to take part in a focus group on Zoom.
Passage Bio have developed a Krabbe Disease newsletter to help explain their GALax-C clinical trial
Krabbe Disease Newsletter – Krabbe Disease Clinical Development Program Update – May 2022
Community statement from Ionis regarding ION373 trial
Please click on link to read their statement: IONIS Statement 07.06.22